Proprietary Solutions NEW TEXTPrint this Page

<

Adaptive Toolkit from Healogix
The Adaptive Toolbox IQS™ from Healogix provides a new and unique perspective on how treatment decisions are made, informing strategies and tactics that can help a new product break in or an existing product break out.
Adaptive Toolkit from Healogix
Adaptive Toolbox IQD™ from Healogix unmasks the many quick decisions that are made in specific diagnostic and therapeutic scenarios… decisions that affect the success of your product.
Everybody needs a Plan A—a comprehensive go to market strategy for your product in clinical development that is designed to maximize the lifetime revenue potential of your product regardless of the competitive landscape.
Plan B is a rigorous, customer driven process that focuses less on why a brand is in its current position. Instead, what are the opportunities moving forward and most importantly how do you maximize those for you brand.
Based on a rigorous choice-model design, the Difference Engine allows us to present physicians with a significant number of product profiles, patient profiles and market events that describe your market today, tomorrow and into the future.
It used to be a lot easier to bring a development stage drug to the market. ValMax uses a combination of qualitative and quantitative tools in innovative ways to help you see how managed care views your category and your brand.
In today’s biopharma market place, it’s not just coverage that matters, it’s understanding how the access barriers payers erect trade off against your current market share. How many hoops are doctors and patients willing to jump through to obtain the benefits of your product?
Future value identification is a qualitative and quantitative approach that takes the respondent into the world as it may exist 3 to 5 or even 10 years from now to understand how current behaviors might change.
Comparative value assessment is a research process (both qualitative and quantitative). All of the relevant stakeholders are identified and interviewed and the data is integrated and synthesized so a company can decide whether and how to best carry out Phase III trials.
Adaptive Toolkit from Healogix The Adaptive Toolbox™ from Healogix provides a new and unique perspective on how treatment decisions are made, informing strategies and tactics that can help a new product break in or an existing product break out.
Adaptive Toolkit from Healogix Put the new text here.
Everybody needs a Plan A—a comprehensive go to market strategy for your product in clinical development that is designed to maximize the lifetime revenue potential of your product regardless of the competitive landscape.
Plan B is a rigorous, customer driven process that focuses less on why a brand is in its current position. Instead, what are the opportunities moving forward and most importantly how do you maximize those for you brand.
Based on a rigorous choice-model design, the Difference Engine allows us to present physicians with a significant number of product profiles, patient profiles and market events that describe your market today, tomorrow and into the future.
It used to be a lot easier to bring a development stage drug to the market. ValMax uses a combination of qualitative and quantitative tools in innovative ways to help you see how managed care views your category and your brand.
In today’s biopharma market place, it’s not just coverage that matters, it’s understanding how the access barriers payers erect trade off against your current market share. How many hoops are doctors and patients willing to jump through to obtain the benefits of your product?
Future value identification is a qualitative and quantitative approach that takes the respondent into the world as it may exist 3 to 5 or even 10 years from now to understand how current behaviors might change.
Comparative value assessment is a research process (both qualitative and quantitative). All of the relevant stakeholders are identified and interviewed and the data is integrated and synthesized so a company can decide whether and how to best carry out Phase III trials.